EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative methylome and transcriptome analyses identify LHX3 as an epigenetically downregulated marker with tumor suppressive properties in breast cancer

Kokab Farooq, Sheereen Gull, Zubia Farooq, Muhammad Talal Amin iD, Rana Salman Anjum, Muhammad Hassan Sarfraz, Ajaz Ahmad, Naveed Shahzad

PLOS One · 2026

DOI: 10.1371/journal.pone.0357378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Kokab Farooq und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, University of the Punjab, Lahore, Pakistan. Hauptthemen laut MEDLINE: Breast Neoplasms, DNA Methylation, Gene Expression Regulation, Neoplastic, Transcription Factors. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) remains a major global health concern, with rising incidence and mortality rates. Early diagnosis of BC plays an important role in its prevention. However, number of clinically validated biomarkers that enable accurate and minimally invasive diagnosis are still insufficient. Epigenetic modifications, particularly hypermethylation-mediated inactivation of numerous tumor suppressor genes occur early in tumorigenesis and are detectable even before the clinical onset, making them promising candidates for early diagnosis. Therefore, this study aimed to identify breast cancer-associated epigenetically regulated genes with potential diagnostic and biological relevance. A set of forty genes that displayed both hypermethylation and downregulation in BC were initially identified through bioinformatics analysis of publicly available datasets. Based on Gene Ontology (GO) and Reactome pathway enrichment analyses, eight genes were subsequently shortlisted for experimental analysis. Among these eight genes, LHX3 was significantly downregulated in both MCF-7 and MDA-MB-231 cells and in all tested BC tissue samples. LHX3 promoter hypermethylation was found in 80% of tumor tissues, compared to 32% in matched normal tissues. Aberrant LHX3 promoter methylation was significantly associated with metastasis status (P = 0.0002), with higher methylation in non-metastatic tumors, tumor size ≤20 mm (P = 0.002), and advanced tumor stage (P = 0.005). Given the complex pattern of these associations, findings were interpreted cautiously. Treatment with 5-aza-2’-deoxycytidine reversed promoter hypermethylation and restored LHX3 expression in MDA-MB-231 and MCF-7 cells. Additionally, ectopic expression of LHX3 not only reduced migration and proliferation but also induced cell death in BC cells. Our study provided the first evidence of epigenetically induced silencing of LHX3 and its anti-tumor role in BC. Furthermore, our findings support LHX3 as a candidate epigenetically regulated biomarker with tumor-suppressive properties in BC; however, independent cohort validation, quantitative methylation assays, and stage/subtype-stratified analyses are required before its diagnostic or prognostic utility can be established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDNA MethylationGene Expression Regulation, NeoplasticTranscription FactorsLIM-Homeodomain ProteinsEpigenesis, GeneticBiomarkers, TumorEpigenomeHumansFemaleDown-RegulationPromoter Regions, GeneticGene Expression ProfilingMCF-7 CellsMDA-MB-231 CellsGenes, Tumor SuppressorCell Line, Tumor

Substanzen

Transcription FactorsLIM-Homeodomain ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • School of Biological Sciences, University of the Punjab, Lahore, Pakistan.
  • Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan.
  • Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium.
  • Forman Christian College, (A Chartered University), Lahore, Pakistan.
  • Department of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America.
  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: Muhammad Talal Amin

Zitieren

APA

Farooq, K., Gull, S., Farooq, Z., Amin, M. T., Anjum, R. S., Sarfraz, M. H., Ahmad, A., & Shahzad, N. (2026). Integrative methylome and transcriptome analyses identify LHX3 as an epigenetically downregulated marker with tumor suppressive properties in breast cancer. PLOS One. https://doi.org/10.1371/journal.pone.0357378

Vancouver

Farooq K, Gull S, Farooq Z, Amin MT, Anjum RS, Sarfraz MH, et al. Integrative methylome and transcriptome analyses identify LHX3 as an epigenetically downregulated marker with tumor suppressive properties in breast cancer. PLOS One. 2026. doi:10.1371/journal.pone.0357378

BibTeX
@article{Farooq2026,
  author = {Farooq, Kokab and Gull, Sheereen and Farooq, Zubia and Amin, Muhammad Talal and Anjum, Rana Salman and Sarfraz, Muhammad Hassan and Ahmad, Ajaz and Shahzad, Naveed},
  title = {Integrative methylome and transcriptome analyses identify LHX3 as an epigenetically downregulated marker with tumor suppressive properties in breast cancer},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0357378}
}
Kostenlos starten →